Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28313535 | 0.81 | KMT2A (0.62) | KMT2AAXLADORA3ADORA2AADORA1 | |
| SCHEMBL22347977 | 0.78 | KMT2A (0.47) | KMT2AAXLSYKADORA3ADORA2A | |
| SCHEMBL29390429 | 0.78 | KMT2A (0.47) | KMT2AAXLSYKADORA3ADORA2A | |
| SCHEMBL22348506 | 0.78 | KMT2A (0.55) | KMT2AAXLSYKADORA3ADORA2A | |
| SCHEMBL6424706 | 0.77 | KMT2A (0.60) | KMT2AAXLADORA3ADORA2AADORA1 | |
| SCHEMBL29526968 | 0.76 | MAPK8 (0.61) | KMT2AMAPK8SYKJAK2STAT6 | |
| SCHEMBL21593677 | 0.76 | KMT2A (0.59) | KMT2AAXLADORA3ADORA2AADORA1 | |
| SCHEMBL30496647 | 0.75 | SYK (0.61) | KMT2AMAPK8SYKJAK2STAT6 | |
| SCHEMBL26919488 | 0.75 | SYK (0.61) | KMT2AMAPK8SYKJAK2STAT6 | |
| SCHEMBL2816574 | 0.74 | NFKB1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-1963282-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | KMT2A 4091/4885AXL 326/4885MAPK8 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.